Effect of Prophylactic Versus Preemptive Lamivudine Treatment and Tenofovir on HBsAg (+) Kidney Transplant Recipients


Ruhi C. , SÜLEYMANLAR İ., KOÇAK H., Dinckan A., Ersoy F., SÜLEYMANLAR G.

EXPERIMENTAL AND CLINICAL TRANSPLANTATION, vol.13, no.1, pp.35-40, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 1
  • Publication Date: 2015
  • Doi Number: 10.6002/ect.2013.0280
  • Title of Journal : EXPERIMENTAL AND CLINICAL TRANSPLANTATION
  • Page Numbers: pp.35-40

Abstract

Objectives: Chronic hepatitis B virus infection remains a clinical problem for HBsAg (+) kidney transplant recipients. Lamivudine is the approved treatment; however, there are contrary views about optimal initiation. In case of resistance, novel nucleoside analogs should be considered but experience is limited.